Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 1
1963 1
1964 1
1965 1
1968 1
1969 1
1970 2
1971 5
1972 6
1973 12
1974 7
1975 11
1976 14
1977 9
1978 19
1979 21
1980 15
1981 23
1982 39
1983 51
1984 89
1985 115
1986 114
1987 128
1988 173
1989 140
1990 152
1991 146
1992 176
1993 231
1994 174
1995 215
1996 245
1997 315
1998 414
1999 536
2000 659
2001 777
2002 851
2003 956
2004 1065
2005 1180
2006 1133
2007 1234
2008 1254
2009 1211
2010 1235
2011 1350
2012 1356
2013 1424
2014 1637
2015 1664
2016 1540
2017 1655
2018 1726
2019 1809
2020 2253
2021 2593
2022 2588
2023 2550
2024 2748
2025 3159
2026 626

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41,789 results

Results by year

Filters applied: . Clear all
Page 1
Dendritic cell maturation in cancer.
Moon CY, Belabed M, Park MD, Mattiuz R, Puleston D, Merad M. Moon CY, et al. Nat Rev Cancer. 2025 Apr;25(4):225-248. doi: 10.1038/s41568-024-00787-3. Epub 2025 Feb 7. Nat Rev Cancer. 2025. PMID: 39920276 Review.
Dendritic cells (DCs) are specialized antigen-presenting cells that are present at low abundance in the circulation and tissues; they serve as crucial immune sentinels by continually sampling their environment, migrating to secondary lymphoid or …
Dendritic cells (DCs) are specialized antigen-presenting cells that are present at low abundance in the c …
Dendritic Cell and Cancer Therapy.
Galati D, Zanotta S. Galati D, et al. Int J Mol Sci. 2023 Feb 20;24(4):4253. doi: 10.3390/ijms24044253. Int J Mol Sci. 2023. PMID: 36835665 Free PMC article.
Dendritic cells (DCs) are acknowledged as the most potent professional antigen-presenting cells (APCs), able to induce adaptive immunity and support the innate immune response [...]....
Dendritic cells (DCs) are acknowledged as the most potent professional antigen-presenting cells (APCs), a …
Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy.
Qian D, Li J, Huang M, Cui Q, Liu X, Sun K. Qian D, et al. Biomed Pharmacother. 2023 Jun;162:114685. doi: 10.1016/j.biopha.2023.114685. Epub 2023 Apr 12. Biomed Pharmacother. 2023. PMID: 37058818 Free article. Review.
Breast cancer (BC) is the most common cancer in women worldwide. Although substantial progress has been made in the diagnosis and treatment of breast cancer, the efficacy and side effects of traditional treatment methods are still unsatisfactory. In recent ye …
Breast cancer (BC) is the most common cancer in women worldwide. Although substantial progress has been made in the diagnosis …
Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity.
Wiernicki B, Maschalidi S, Pinney J, Adjemian S, Vanden Berghe T, Ravichandran KS, Vandenabeele P. Wiernicki B, et al. Nat Commun. 2022 Jun 27;13(1):3676. doi: 10.1038/s41467-022-31218-2. Nat Commun. 2022. PMID: 35760796 Free PMC article.
Here we present an inducible model of ferroptosis, distinguishing three phases in the process-'initial' associated with lipid peroxidation, 'intermediate' correlated with ATP release and 'terminal' recognized by HMGB1 release and loss of plasma membrane integrity-that serves as t …
Here we present an inducible model of ferroptosis, distinguishing three phases in the process-'initial' associated with lipid peroxidation, …
Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens.
Kamigaki T, Takimoto R, Okada S, Ibe H, Oguma E, Goto S. Kamigaki T, et al. Anticancer Res. 2024 Sep;44(9):3713-3724. doi: 10.21873/anticanres.17196. Anticancer Res. 2024. PMID: 39197920 Review.
Cancer immunotherapy activates the host immune system against tumor cells and has the potential to lead to the development of innovative strategies for cancer treatment. ...Whereas there are various platforms for neoantigen vaccines, combined immuno-therapies …
Cancer immunotherapy activates the host immune system against tumor cells and has the potential to lead to the development of …
Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities.
Fu C, Ma T, Zhou L, Mi QS, Jiang A. Fu C, et al. Immunol Invest. 2022 Nov;51(8):2133-2158. doi: 10.1080/08820139.2022.2109486. Epub 2022 Aug 10. Immunol Invest. 2022. PMID: 35946383 Review.
As the most potent professional antigen presenting cells, dendritic cells (DCs) have the ability to activate both naive CD4 and CD8 T cells. Recognized for their exceptional ability to cross-present exogenous antigens to prime naive antig …
As the most potent professional antigen presenting cells, dendritic cells (DCs) have the ability to activ …
Advances in dendritic cell vaccination therapy of cancer.
Najafi S, Mortezaee K. Najafi S, et al. Biomed Pharmacother. 2023 Aug;164:114954. doi: 10.1016/j.biopha.2023.114954. Epub 2023 May 29. Biomed Pharmacother. 2023. PMID: 37257227 Free article. Review.
Nevertheless, development of anticancer vaccines as valuable targets in human health has faced challenges and requires further optimizations. Dendritic cells (DCs) are the most potent antigen presenting cells (APCs) that play essential roles in …
Nevertheless, development of anticancer vaccines as valuable targets in human health has faced challenges and requires further optimizations …
Plasmacytoid dendritic cell in immunity and cancer.
Mitchell D, Chintala S, Dey M. Mitchell D, et al. J Neuroimmunol. 2018 Sep 15;322:63-73. doi: 10.1016/j.jneuroim.2018.06.012. Epub 2018 Jun 26. J Neuroimmunol. 2018. PMID: 30049538 Review.
Plasmacytoid dendritic cells (pDCs) comprise a subset of dendritic cells characterized by their ability to produce large amount of type I interferon (IFN-I/alpha). ...In addition to IFN-alpha production, pDCs can also act as antigen presentin …
Plasmacytoid dendritic cells (pDCs) comprise a subset of dendritic cells characterized by their ability to produ …
Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting.
Achmad H, Saleh Ibrahim Y, Mohammed Al-Taee M, Gabr GA, Waheed Riaz M, Hamoud Alshahrani S, Alexis Ramírez-Coronel A, Turki Jalil A, Setia Budi H, Sawitri W, Elena Stanislavovna M, Gupta J. Achmad H, et al. Int Immunopharmacol. 2022 Dec;113(Pt B):109434. doi: 10.1016/j.intimp.2022.109434. Epub 2022 Nov 16. Int Immunopharmacol. 2022. PMID: 36402068 Review.
To increase the therapeutic effects of nanovaccines in cancer therapy, dendritic cell (DC) targeting through the modulation of the structure of the vaccines, such as using DC-specific ligands, has attracted extensive interest. Here, we reviewed the various fo …
To increase the therapeutic effects of nanovaccines in cancer therapy, dendritic cell (DC) targeting through the modula …
Ex vivo pulsed dendritic cell vaccination against cancer.
Gu YZ, Zhao X, Song XR. Gu YZ, et al. Acta Pharmacol Sin. 2020 Jul;41(7):959-969. doi: 10.1038/s41401-020-0415-5. Epub 2020 May 4. Acta Pharmacol Sin. 2020. PMID: 32366940 Free PMC article. Review.
As the most powerful antigen-presenting cell type, dendritic cells (DCs) can induce potent antigen-specific immune responses in vivo, hence becoming optimal cell population for vaccination purposes. DCs can be derived ex vivo in quantity …
As the most powerful antigen-presenting cell type, dendritic cells (DCs) can induce potent antigen-specif …
41,789 results
You have reached the last available page of results. Please see the User Guide for more information.